{"id":"placebo-to-ezetimibe-atorvastatin","safety":{"commonSideEffects":[{"rate":"null","effect":"Musculoskeletal pain"},{"rate":"null","effect":"Liver enzyme elevation"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Ezetimibe works by binding to the Niemann-Pick C1-like 1 (NPC1L1) protein on intestinal cells, preventing the absorption of cholesterol from the diet. Atorvastatin, on the other hand, inhibits the enzyme HMG-CoA reductase, which is involved in the production of cholesterol in the liver. By reducing both dietary and endogenous cholesterol, ezetimibe/atorvastatin helps to lower LDL cholesterol levels in the blood.","oneSentence":"Ezetimibe inhibits the absorption of cholesterol in the small intestine, while atorvastatin inhibits HMG-CoA reductase to reduce cholesterol production in the liver.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:44.620Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperlipidemia"},{"name":"Homozygous familial hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT05930028","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2023-07-13","conditions":"Essential Hypertension, Primary Hypercholesterolemia","enrollment":148},{"nctId":"NCT00092638","phase":"PHASE3","title":"An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-05","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":450},{"nctId":"NCT00092625","phase":"PHASE3","title":"Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-03","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":442},{"nctId":"NCT00110435","phase":"PHASE3","title":"A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Type 2 Diabetes Mellitus, Hypercholesterolemia","enrollment":1229},{"nctId":"NCT00535405","phase":"PHASE3","title":"A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-11","conditions":"Hypercholesterolemia","enrollment":1289},{"nctId":"NCT00409773","phase":"PHASE3","title":"Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-01","conditions":"Hypercholesterolemia, Metabolic Syndrome","enrollment":1143},{"nctId":"NCT02550288","phase":"PHASE3","title":"A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2015-09-29","conditions":"Hypercholesterolemia","enrollment":309},{"nctId":"NCT03768427","phase":"PHASE3","title":"Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2019-05-27","conditions":"Hypercholesterolemia","enrollment":454},{"nctId":"NCT00418834","phase":"PHASE3","title":"Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-01","conditions":"Hypercholesterolemia","enrollment":1053},{"nctId":"NCT00276458","phase":"PHASE3","title":"To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":"Hypercholesterolemia","enrollment":196},{"nctId":"NCT03867110","phase":"PHASE3","title":"An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-03-06","conditions":"Hypercholesterolemia","enrollment":628},{"nctId":"NCT03882892","phase":"PHASE3","title":"Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-02-02","conditions":"Hypercholesterolemia","enrollment":400},{"nctId":"NCT03884452","phase":"PHASE3","title":"Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-05-03","conditions":"Familial Hypercholesterolemia","enrollment":50},{"nctId":"NCT03867318","phase":"PHASE3","title":"Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-04-24","conditions":"Hypercholesterolemia","enrollment":621},{"nctId":"NCT05970679","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2022-08-17","conditions":"Hypercholesterolemia, Dyslipidemia","enrollment":252},{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":"Hypercholesterolaemia","enrollment":153},{"nctId":"NCT01763866","phase":"PHASE3","title":"LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-15","conditions":"Hyperlipidemia","enrollment":2067},{"nctId":"NCT01516879","phase":"PHASE3","title":"Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-01-05","conditions":"Hypercholesterolemia","enrollment":905},{"nctId":"NCT05131997","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2021-11-16","conditions":"Primary Hypercholesterolemia","enrollment":290},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT02476006","phase":"PHASE3","title":"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-06-23","conditions":"Hypercholesterolemia","enrollment":998},{"nctId":"NCT00651404","phase":"PHASE3","title":"Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":137},{"nctId":"NCT00202904","phase":"PHASE4","title":"Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Hypercholesterolemia, Coronary Heart Disease","enrollment":81},{"nctId":"NCT00319449","phase":"PHASE4","title":"Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09","conditions":"Hypercholesterolemia, Coronary Arteriosclerosis","enrollment":22},{"nctId":"NCT01370603","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-09","conditions":"Hypercholesterolemia","enrollment":328},{"nctId":"NCT01370590","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-09","conditions":"Hypercholesterolemia","enrollment":406},{"nctId":"NCT01709513","phase":"PHASE3","title":"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-09-30","conditions":"Hypercholesterolemia","enrollment":314},{"nctId":"NCT03051100","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2017-01-19","conditions":"Hypercholesterolemia","enrollment":63},{"nctId":"NCT00687076","phase":"PHASE4","title":"Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2004-04","conditions":"Peripheral Arterial Disease","enrollment":102},{"nctId":"NCT02227784","phase":"PHASE3","title":"A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-10","conditions":"Hyperlipidemia","enrollment":366},{"nctId":"NCT02715726","phase":"PHASE3","title":"Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-27","conditions":"Hypercholesterolemia","enrollment":615},{"nctId":"NCT00965055","phase":"PHASE3","title":"Ezetimibe in Patients Hypo-responsive to Statins","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2009-09","conditions":"High Cholesterol, Coronary Artery Disease","enrollment":2},{"nctId":"NCT01218204","phase":"PHASE2","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-14","conditions":"Dyslipidaemias, Dyslipidemias","enrollment":287},{"nctId":"NCT02055976","phase":"PHASE2","title":"Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03","conditions":"Hypercholesterolemia","enrollment":218},{"nctId":"NCT02584504","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-30","conditions":"Hypercholesterolemia","enrollment":163},{"nctId":"NCT01984424","phase":"PHASE3","title":"Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-12-10","conditions":"Hyperlipidemia","enrollment":511},{"nctId":"NCT00559962","phase":"PHASE2","title":"Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2007-10","conditions":"Hyperlipidemia","enrollment":260},{"nctId":"NCT00127218","phase":"PHASE3","title":"High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2003-09","conditions":"Atherosclerosis, Cardiovascular Disease","enrollment":145},{"nctId":"NCT01644188","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Hypercholesterolemia","enrollment":720},{"nctId":"NCT02451098","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of CKD-391","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-03","conditions":"Hyperlipidemia","enrollment":385},{"nctId":"NCT01730040","phase":"PHASE3","title":"Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-10","conditions":"Hypercholesterolemia","enrollment":355},{"nctId":"NCT01385631","phase":"PHASE4","title":"Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction.","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2011-06","conditions":"ST-Segment Elevation Myocardial Infarction","enrollment":87},{"nctId":"NCT00639158","phase":"PHASE3","title":"Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-02","conditions":"Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia","enrollment":543}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to ezetimibe/atorvastatin","genericName":"Placebo to ezetimibe/atorvastatin","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ezetimibe inhibits the absorption of cholesterol in the small intestine, while atorvastatin inhibits HMG-CoA reductase to reduce cholesterol production in the liver. Used for Hyperlipidemia, Homozygous familial hypercholesterolemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}